Trade Report: Today, Dynavax Technologies Corp. (DVAX) Stake Increased by State Board of Administration of Florida Retirement System

Today, Dynavax Technologies Corp. (DVAX) Stake Increased by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System raised its stake in Dynavax Technologies Corp. (NASDAQ:DVAX) by 12.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,836 shares of the biopharmaceutical company’s stock after buying an additional 1,779 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Dynavax Technologies Corp. were worth $231,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in DVAX. Boston Advisors LLC increased its position in Dynavax Technologies Corp. by 1.3% in the second quarter. Boston Advisors LLC now owns 12,330 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 155 shares during the period. Falcon Point Capital LLC increased its position in Dynavax Technologies Corp. by 12.7% in the second quarter. Falcon Point Capital LLC now owns 21,753 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 2,458 shares during the period. California State Teachers Retirement System increased its position in Dynavax Technologies Corp. by 5.0% in the second quarter. California State Teachers Retirement System now owns 81,505 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 3,851 shares during the period. Pictet Asset Management Ltd. increased its position in Dynavax Technologies Corp. by 2.0% in the first quarter. Pictet Asset Management Ltd. now owns 221,212 shares of the biopharmaceutical company’s stock valued at $3,566,000 after buying an additional 4,341 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in Dynavax Technologies Corp. during the second quarter valued at $107,000. Hedge funds and other institutional investors own 83.72% of the company’s stock.

Dynavax Technologies Corp. (NASDAQ:DVAX) traded up 3.45% during midday trading on Tuesday, hitting $10.50. The stock had a trading volume of 175,982 shares. The stock’s market cap is $404.22 million. Dynavax Technologies Corp. has a 12-month low of $10.05 and a 12-month high of $29.86. The company’s 50-day moving average price is $11.94 and its 200 day moving average price is $15.35.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.07. The business earned $2.65 million during the quarter, compared to analyst estimates of $1.58 million. Dynavax Technologies Corp. had a negative return on equity of 64.43% and a negative net margin of 2,068.75%. The business’s quarterly revenue was up 70.8% on a year-over-year basis. During the same period last year, the business earned ($0.80) EPS. On average, equities research analysts predict that Dynavax Technologies Corp. will post ($2.96) earnings per share for the current fiscal year.

Several brokerages have commented on DVAX. Cowen and Company restated an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. Zacks Investment Research upgraded Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Monday, June 27th. RBC Capital Markets restated a “sector perform” rating and set a $16.00 price target on shares of Dynavax Technologies Corp. in a research note on Wednesday, September 7th. William Blair restated a “buy” rating and set a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. Finally, S&P Equity Research upped their price target on Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $25.86.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Related posts

Leave a Comment